01:21 AM EDT, 07/13/2026 (MT Newswires) -- Santhera Pharmaceuticals (SANN.SW) extended its exclusive distribution deal for its Duchenne muscular dystrophy drug, Agamree, with Biomedica to include five more countries. The expanded agreement covers Georgia, Kazakhstan, Belarus, Azerbaijan, and Uzbekistan, according to a Monday release. Biomedica was appointed as a distributor for Agamree in October 2025, while the Swiss specialty pharmaceutical company receives a certain percentage of the net sales.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.